US EPA ARCHIVE DOCUMENT
MEMORANDUM

SUBJECT: Special neurotoxicity testing for lindane.

TOX CHEM No.: 527
TOX PROJECT No.: 1-0739
Submission No.: S391313

FROM: John Doherty
Section IV, Toxicology Branch I
Health Effects Division (H5709C)

TO: Janet Auerbach
Project Manager #60
Special Review and Reregistration Division
(H5708C)

THROUGH: Marion Copley, DVM, Section Head
Section IV, Toxicology Branch I
Health Effects Division (H5709C)

and Karl Baetcke, PhD., Chief
Toxicology Branch
Health Effects Division (H7509C)

Margaret Rice, Special Review Manager for lindane, has raised the issue for the need for acute (81-8-SS) and 90-day subchronic (82-5 B) neurotoxicity testing for lindane. Ms. Rice has further requested that Toxicology Branch I (TB-I) send a memo to you addressing the issue for the need for such testing.

In response to Ms. Rice's request, TB - I had internal discussions which included Dr. William Sette, HED specialist in neurotoxicity and a principal author of the proposed neurotoxicity testing guidelines. It was concluded that both acute and subchronic neurotoxicity testing will be required to support the continued existing registrations for lindane. The registrants of lindane should be advised to contact the Agency through the product manager for appropriate protocols for neurotoxicity testing.